The evolution of therapeutic strategies includes: Targeted Therapies: PARP inhibitors, immune checkpoint inhibitors (ICIs), and novel antibody-drug conjugates (ADCs) are transforming treatment ...

Although the finding is interesting, the finding that FGFR2 is amplified in gastric cancer and that FGFR inhibitors have some effect on treating gastric cancer is not novel. The data quality is not ...

Key biomarkers and cutting-edge treatments, such as PARP inhibitors and immunotherapy combinations, drive advancements in TNBC outcomes Novotech, the leading global full-service clinical Contract ...

SYDNEY--(BUSINESS WIRE)--Novotech, the leading global full-service clinical Contract Research Organization (CRO), has released a comprehensive report analyzing the global clinical trial and drug ...

These alterations may affect tumor microenvironment and outcomes with immune checkpoint inhibitors (ICIs) in aUC. We identified patients with available ... OS]) with ICI were compared between patients ...

1月13日，强生创新制药官方公众号披露，强生公司宣布，旗下创新治疗药物博珂® (厄达替尼片)正式获得国家药品监督管理局批准，用于治疗携带易 ...

A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

In addition, many critical issues still need to be resolved, including how to identify the patients who are most likely to benefit from treatment and how to determine the best combination of FGFR ...